Last reviewed · How we verify
NCT00719225
A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
trial testing Belatacept in Renal Transplantation. No longer available.
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Belatacept (BELATACEPT) — full drug profile →
Conditions studied
- Renal Transplantation — all drugs for Renal Transplantation →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Renal Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: * unable to construct an adequate immunosuppression regimen due to nonrenal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR * at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The past, present, and future of costimulation blockade in organ transplantation.
Schroder PM, Fitch ZW, Schmitz R, Choi AY, et al · · 2019 · cited 43× · PMID 31157670 · DOI 10.1097/mot.0000000000000656
Verify or expand the search:
- PubMed search for NCT00719225
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Belatacept
Trials testing the same drug.
- NCT06918990 — Treatment of Antibody-Mediated Rejection (ABMR) With CarBel · Phase 2 · not yet recruiting
- NCT06291077 — Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BEL · Phase 4 · not yet recruiting
- NCT06478017 — Belatacept in Heart Transplantation · Phase 2 · recruiting
- NCT06055608 — Advancing Transplantation Outcomes in Children · Phase 2 · recruiting
- NCT06307808 — Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination · unknown
Other recruiting trials for Renal Transplantation
Currently open trials in the same condition.
- NCT07294183 — The Effect of Emotion-Focused Intervention on Emotion Regulation and Well-Being of Individuals With Transplantation · NA · recruiting
- NCT07045467 — Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study · Phase 1 · recruiting
- NCT06406179 — Evaluation of the Efficacy of Dd-cfDNA in Routine Patient Care in Kidney Transplant Recipients" · NA · recruiting
- NCT06026592 — Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients · recruiting
- NCT03266393 — Envarsus XR® in Adolescent Renal Transplant Recipients · Phase 4 · active not recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00719225 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 23 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00719225.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing